We observed that amplification of EIF4G1 were prominent in prostate cancer (~ 25%), ovarian cancer (~ 15%), Head and neck cancer (~ 13%) and cervical cancer (~ 12.5%). This evidence concerns the gene EIF4G1 and ovarian carcinoma.